Temocapril HClCAS# 110221-44-8 |
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Losartan Potassium (DuP 753)
Catalog No.:BCC1080
CAS No.:124750-99-8
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Rosuvastatin Calcium
Catalog No.:BCC3853
CAS No.:147098-20-2
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 110221-44-8 | SDF | Download SDF |
| PubChem ID | 443873 | Appearance | Powder |
| Formula | C23H29ClN2O5S2 | M.Wt | 513.07 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (194.91 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;hydrochloride | ||
| SMILES | CCOC(=O)C(CCC1=CC=CC=C1)NC2CSC(CN(C2=O)CC(=O)O)C3=CC=CS3.Cl | ||
| Standard InChIKey | XDDQNOKKZKHBIX-ASBZXGSUSA-N | ||
| Standard InChI | InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Temocapril Hydrochloride is a long-acting angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension.
Target: ACE
Temocapril hydrochloride is a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency [1]. Temocapril is regarded as an ACE inhibitor the disposition and efficacy of which are little affected in patients with impaired liver function [2]. References: | |||||
Temocapril HCl Dilution Calculator
Temocapril HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9491 mL | 9.7453 mL | 19.4905 mL | 38.981 mL | 48.7263 mL |
| 5 mM | 0.3898 mL | 1.9491 mL | 3.8981 mL | 7.7962 mL | 9.7453 mL |
| 10 mM | 0.1949 mL | 0.9745 mL | 1.9491 mL | 3.8981 mL | 4.8726 mL |
| 50 mM | 0.039 mL | 0.1949 mL | 0.3898 mL | 0.7796 mL | 0.9745 mL |
| 100 mM | 0.0195 mL | 0.0975 mL | 0.1949 mL | 0.3898 mL | 0.4873 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Temocapril HCl
- Ginsenoside Rc
Catalog No.:BCN1072
CAS No.:11021-14-0
- Ginsenoside Rb2
Catalog No.:BCN1064
CAS No.:11021-13-9
- Cochliophilin A
Catalog No.:BCC8154
CAS No.:110204-45-0
- Malonylginsenoside Rb(1)
Catalog No.:BCC9230
CAS No.:88140-34-5
- 1,5,8-Trihydroxy-3-methoxy-2-prenylxanthone
Catalog No.:BCN1623
CAS No.:110187-11-6
- JZL184
Catalog No.:BCC4790
CAS No.:1101854-58-3
- Ouabain Octahydrate
Catalog No.:BCC5211
CAS No.:11018-89-6
- 4-Galloylquinic acid
Catalog No.:BCN3733
CAS No.:110170-37-1
- Methyl hesperidin
Catalog No.:BCN6341
CAS No.:11013-97-1
- Indoximod (NLG-8189)
Catalog No.:BCC5584
CAS No.:110117-83-4
- Ascomycin
Catalog No.:BCN8286
CAS No.:11011-38-4
- des-His1-[Glu9]-Glucagon (1-29) amide
Catalog No.:BCC5885
CAS No.:110084-95-2
- Nothofagin
Catalog No.:BCN3787
CAS No.:11023-94-2
- Digitonin
Catalog No.:BCN3734
CAS No.:11024-24-1
- (-)-beta-Peltatin-5-O-beta-D-glucopyranoside
Catalog No.:BCN3607
CAS No.:11024-59-2
- Ganoderic acid N
Catalog No.:BCN2438
CAS No.:110241-19-5
- Ganoderenic acid E
Catalog No.:BCN8241
CAS No.:110241-23-1
- Amrubicin
Catalog No.:BCC3640
CAS No.:110267-81-7
- Agnuside
Catalog No.:BCN5990
CAS No.:11027-63-7
- Bacoside A
Catalog No.:BCC8127
CAS No.:11028-00-5
- CI 966 hydrochloride
Catalog No.:BCC7010
CAS No.:110283-66-4
- Santalol
Catalog No.:BCN8352
CAS No.:11031-45-1
- α-Bungarotoxin
Catalog No.:BCC7264
CAS No.:11032-79-4
- FD-838
Catalog No.:BCN6396
CAS No.:110341-78-1
Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.[Pubmed:8427943]
Biopharm Drug Dispos. 1993 Jan;14(1):41-50.
Despite the usefulness of angiotensin converting enzyme (ACE; EC 3.4.15.1) inhibitors for patients with renal insufficiency, some hesitation has been exercised in applying ACE inhibitors to the treatment of such patients because most ACE inhibitors are excreted mainly into the urine. In this context, development of an ACE inhibitor which is excreted into the bile has been sought. The pharmacokinetic properties of the novel ACE inhibitor, temocapril hydrochloride (Temocapril HCl; CS-622), were investigated in six healthy volunteers. This drug is excreted mainly into the bile in animal studies. Temocapril HCl was given in a single dose of 0.5, 1.0, and 2.0 mg, and 36, 44, and 38 per cent of the administered drug was excreted in the feces and 17, 19, and 24 per cent in the urine as the de-esterified active diacid form (the diacid metabolite) within 48 h, respectively. The plasma ACE activity was markedly inhibited. No abnormal clinical findings suggestive of side-effects were observed. Thus, from the pharmacokinetic standpoint, Temocapril HCl is expected to be a useful drug for patients with renal dysfunction.
